Aldeyra Therapeutics Schedules Webcast and Conference Call to Report First-Quarter 2021 Financial Results and Discuss Recent Business Highlights

b'Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Thursday, April 29, 2021
Information
Tags: 
Biotechnology, FDA, Health, Pharmaceutical, Clinical trials, Vitreoretinopathy, Dihydrofolate reductase inhibitor, Reductase, Dihydrofolate reductase, Chemistry, Branches of biology
Geotags: 
United States, Massachusetts
⚠generated by AI ↴
Summary
Key Points: 
  • b'Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m.
  • ET Thursday, May 6, 2021 to report financial results for the quarter ended March 31, 2021 and discuss recent business highlights.\nThe dial-in numbers are (866) 211-4098 for domestic callers and (647) 689-6613 for international callers.
  • The company\xe2\x80\x99s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy.
  • For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn , Facebook , and Twitter .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210429005131/en/\n'


Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Thursday, May 6, 2021 to report financial results for the quarter ended March 31, 2021 and discuss recent business highlights.

The dial-in numbers are (866) 211-4098 for domestic callers and (647) 689-6613 for international callers. The Conference ID number is 6779202. A live webcast of the conference call will also be available on the Investors & Media page of the company’s corporate website at https://ir.aldeyra.com.

After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for 90 days.

About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead investigational compounds, reproxalap and ADX-629, target RASP (reactive aldehyde species), which are elevated in ocular and systemic inflammatory disease and result in cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.

Copyright: 
Copyright Business Wire 2021